Supply of goods by Alphapharm Pty Limited

Overview

The Therapeutic Goods Act 1989 (the Act) was enacted to regulate the supply of therapeutic goods in Australia, aiming to ensure that such goods are safe, of acceptable quality, and properly labelled. This legislation was introduced to address the need for a comprehensive regulatory framework governing the therapeutic goods industry, ensuring that products available to consumers meet necessary standards for health and safety. The Act is administered by the Australian Parliament and its policy objective is to protect public health by controlling the quality and safety of therapeutic goods through regulation. This particular notice issued by Mayada Kayali, a delegate of the Secretary to the Department of Health and Ageing, pertains to the consent granted to Alphapharm Pty Limited for the supply of certain nicotine patches that do not fully comply with labelling standards. This consent, however, is conditional upon the goods meeting all other regulatory requirements, thus ensuring that the therapeutic goods supplied to the market are safe and of appropriate quality despite the labelling non-compliance.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood and blood components. This particular legislative excerpt pertains to the consent granted under sections 14 and 14A of the Act, allowing a specified entity to supply goods that do not fully comply with certain labelling requirements. The consent issued by Mayada Kayali, as a delegate of the Secretary to the Department of Health and Ageing, is directed at Alphapharm Pty Limited, a pharmaceutical company located in New South Wales. The consent applies specifically to certain batch numbers of nicotine patches, which fail to comply with the Therapeutic Goods Order No. 69 concerning label prefixes for medicines. However, this consent is conditional upon the goods meeting all other regulatory standards. The consent is geographically limited to the Commonwealth of Australia and applies only to the specified batches of the therapeutic goods in question.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 provide a mechanism for the delegate of the Secretary to the Department of Health and Ageing to consent to the supply of therapeutic goods that do not fully comply with certain labelling requirements, under specific conditions. In this case, the delegate has given consent for Alphapharm Pty Limited to supply nicotine patches (AUST R 77927, AUST R 77929, and AUST R 77930) whose labels do not prefix the batch and expiry details with the required "AUST R" prefix. This consent is explicitly limited to certain batch numbers: 489800, 497900, 497300, and 480400. This consent is given under the condition that the goods comply with all other aspects of the Therapeutic Goods Order No. 69. The obligations and requirements imposed by this Act on Alphapharm Pty Limited and the delegate include ensuring that the supplied nicotine patches meet all other labelling standards as stipulated by the Therapeutic Goods Order No. 69. The delegate’s consent is contingent on the condition that all other labelling requirements are adhered to, thereby maintaining the integrity and safety of the therapeutic goods supplied. Alphapharm Pty Limited must ensure that the specified batch numbers comply with all other labelling standards to avoid any breach of the conditions imposed by the delegate. In the event of a breach of the conditions set forth by the delegate's consent, there may be significant consequences. Section 15(1) of the Therapeutic Goods Act 1989 stipulates that failure to comply with the conditions may result in the delegate withdrawing the consent. This could lead to the cessation of the supply of the non-compliant goods. Additionally, the Therapeutic Goods Act 1989 contains provisions for both civil and criminal penalties for breaches of its requirements. Civil penalties may include fines, while criminal penalties could involve imprisonment, reflecting the seriousness with which the Act treats non-compliance with therapeutic goods regulations. The maximum penalties for such breaches are detailed in other sections of the Act, which may include substantial fines and imprisonment terms depending on the severity and nature of the breach.